Effect of recombinant human erythropoietin on anticancer drug-induced anaemia.
Anaemia was induced in rats with fluorouracil (5-FU) or cisplatin (CDDP) and the mechanisms of anaemia induction were analysed. Furthermore, the therapeutic effects of recombinant human erythropoietin (rHu Epo) on these anticancer drug-induced anaemias were investigated. In 5-FU-induced anaemia, marked serum erythropoietin (Epo) elevation was observed in inverse correlation to blood Hb concentration and Hb concentration rapidly recovered to normal levels. On the other hand, in CDDP-induced anaemia, serum Epo elevation was modest and the lowered Hb concentration persisted longer. Treatment with rHu Epo significantly improved both anticancer drug-induced anaemias but rHu Epo was more effective on CDDP-induced anaemia. These results suggest that rHu Epo might be useful for the therapy of anaemia associated with anticancer chemotherapy.
Exploratory Research Laboratories, Chugai Pharmaceutical Co. Ltd, Shizuoka, Japan.
T
T
Matsumoto
K
K
Endoh
K
K
Kamisango
K
K
Akamatsu
K
K
Koizumi
M
M
Higuchi
N
N
Imai
H
H
Mitsui
T
T
Kawaguchi
D000740:Anemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000818:Animals; D002945:Cisplatin / Q000009:adverse effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005472:Fluorouracil / Q000009:adverse effects; D006454:Hemoglobins / Q000032:analysis; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D002945:Cisplatin; D005472:Fluorouracil